Cipla & Ethris partner for the development of mRNA-based therapies
Cipla Limited announced that its wholly-owned UK subsidiary, Cipla (EU) Limited has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH , a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation.










